Answers are grounded in this paper and cite their sources.
Demonstrates improved diagnostic accuracy in thrombosis and hemorrhage detection, suggesting advancements in IVD capabilities.
Thrombotic and hemorrhagic diseases have become the leading cause of death globally, with early, accurate, and stratified diagnosis being critical for clinical management. China's in vitro diagnostics (IVD) industry is currently in a period of rapid growth, yet high-end coagulation and hemostasis testing reagents remain heavily dependent on imports, and routine tests fail to meet the demands of precision medicine. This article, guided by clinical application principles, introduces key parameters such as protein C, protein S, vWF factor, and monitoring of novel anticoagulants. It elucidates the development design rationale and key technical points of reagents, product evaluation methods, and proposes a comprehensive industrialization strategy encompassing raw material procurement, production processes, quality control, registration, marketing, and continuous improvement. Feasible solutions for domestic substitution and technological upgrading are also proposed. The study demonstrates that colorimetric substrate-based and coagulation-based methods can achieve internationally comparable levels of accuracy in key factor activity and serum drug concentration detection. Establishing an industrialization model of "R&D–production–registration–market–after-sales" will facilitate the localization of high-end coagulation reagents, reduce clinical costs, and improve disease diagnosis rates. This research lays the foundation and accumulates experience for the development and industrial application of thrombotic and hemostatic IVD products, promoting the autonomous and healthy development of China's IVD industry.
No takes yet. Share an insight, caveat, or question.
Lu Yi (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: